Fragment-Based Discovery of 6-Arylindazole JAK Inhibitors

ACS Medicinal Chemistry Letters

Volumn 7, Issue 6, 2016, Pages 641-646

  Ritzén, Andreas ^a   Sørensen, Morten D ^a   Dack, Kevin N ^a   Greve, Daniel R ^a   Jerre, Anders ^a   Carnerup, Martin A ^a   Rytved, Klaus A ^a   Bagger Bahnsen, Jesper ^a  

^a LEO PHARMA A S   (Denmark)

Author keywords

Fragments; indazoles; JAK inhibitors; phototoxicity; psoriasis

Indexed keywords

ANTIPSORIASIS AGENT; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; JANUS KINASE INHIBITOR; PHENOL; STAT6 PROTEIN; SULFONAMIDE;

ARTICLE; CONFORMATIONAL TRANSITION; HEPATIC CLEARANCE; HUMAN; HUMAN CELL; HYDROGEN BOND; IC50; INTRINSIC CLEARANCE; PHOTOTOXICITY; PRIORITY JOURNAL; PSORIASIS;

EID: 84974625396     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/acsmedchemlett.6b00087     Document Type: Article

References (23)

1. Parisi, R.; Symmons, D. P. M.; Griffiths, C. E. M.; Ashcroft, D. M. Global Epidemiology of Psoriasis: A Systematic Review of Incidence and Prevalence J. Invest. Dermatol. 2013, 133, 377-385 10.1038/jid.2012.339
2. Armstrong, A. W.; Robertson, A. D.; Wu, J.; Schupp, C.; Lebwohl, M. G. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011 JAMA Dermatol. 2013, 149, 1180-1185 10.1001/jamadermatol.2013.5264
3. Kim, J.; Krueger, J. G. The immunopathogenesis of psoriasis Dermatol. Clin. 2015, 33, 13-23 10.1016/j.det.2014.09.002
4. Kupetsky, E. A.; Mathers, A. R.; Ferris, L. K. Anti-cytokine therapy in the treatment of psoriasis Cytokine+ 2013, 61, 704-712 10.1016/j.cyto.2012.12.027
5. Babon, J. J.; Lucet, I. S.; Murphy, J. M.; Nicola, N. A.; Varghese, L. N. The molecular regulation of Janus kinase (JAK) activation Biochem. J. 2014, 462, 1-13 10.1042/BJ20140712
6. Clark, J. D.; Flanagan, M. E.; Telliez, J. B. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases J. Med. Chem. 2014, 57, 5023-5038 10.1021/jm401490p
7. Ghoreschi, K.; Gadina, M. Jakpot! New small molecules in autoimmune and inflammatory diseases Exp. Dermatol. 2014, 23, 7-11 10.1111/exd.12265
8. Hsu, L.; Armstrong, A. W. JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis J. Immunol. Res. 2014, 2014, 283617 10.1155/2014/283617
9. Levy, L. L.; Urban, J.; King, B. A. Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate J. Am. Acad. Dermatol. 2015, 73, 395-399 10.1016/j.jaad.2015.06.045
10. Bissonnette, R.; Papp, K. A.; Poulin, Y.; Gooderham, M.; Raman, M.; Papacharalambous, J.; Wang, C.; Purohit, V.; Mamolo, C.; Mallbris, L.; Ports, W. Efficacy and safety of topical Janus kinase inhibitor tofacitinib in the treatment of atopic dermatitis: results of a Phase 2a randomized clinical trial. Poster presented at 23rd World Congress of Dermatology, Vancouver, Canada, June 8-13, 2015.
11. Papp, K. A.; Menter, A.; Strober, B.; Langley, R. G.; Buonanno, M.; Wolk, R.; Gupta, P.; Krishnaswami, S.; Tan, H.; Harness, J. A. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study Br. J. Dermatol. 2012, 167, 668-677 10.1111/j.1365-2133.2012.11168.x
12. Ports, W. C.; Khan, S.; Lan, S.; Lamba, M.; Bolduc, C.; Bissonnette, R.; Papp, K. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis Br. J. Dermatol. 2013, 169, 137-145 10.1111/bjd.12266
13. Bodor, N.; Buchwald, P. Soft drug design: general principles and recent applications Med. Res. Rev. 2000, 20, 58-101 10.1002/(SICI)1098-1128(200001)20:1<58::AID-MED3>3.0.CO;2-X
14. Antonysamy, S.; Hirst, G.; Park, F.; Sprengeler, P.; Stappenbeck, F.; Steensma, R.; Wilson, M.; Wong, M. Fragment-based discovery of JAK-2 inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 279-282 10.1016/j.bmcl.2008.08.064
15. Wang, T.; Duffy, J. P.; Wang, J.; Halas, S.; Salituro, F. G.; Pierce, A. C.; Zuccola, H. J.; Black, J. R.; Hogan, J. K.; Jepson, S.; Shlyakter, D.; Mahajan, S.; Gu, Y.; Hoock, T.; Wood, M.; Furey, B. F.; Frantz, J. D.; Dauffenbach, L. M.; Germann, U. A.; Fan, B.; Namchuk, M.; Bennani, Y. L.; Ledeboer, M. W. Janus Kinase 2 Inhibitors. Synthesis and Characterization of a Novel Polycyclic Azaindole J. Med. Chem. 2009, 52, 7938-7941 10.1021/jm901383u
16. Wang, T.; Ledeboer, M. W.; Duffy, J. P.; Pierce, A. C.; Zuccola, H. J.; Block, E.; Shlyakter, D.; Hogan, J. K.; Bennani, Y. L. A novel chemotype of kinase inhibitors: Discovery of 3,4-ring fused 7-azaindoles and deazapurines as potent JAK2 inhibitors Bioorg. Med. Chem. Lett. 2010, 20, 153-156 10.1016/j.bmcl.2009.11.021
17. Beno, B. R.; Yeung, K.-S.; Bartberger, M. D.; Pennington, L. D.; Meanwell, N. A. A Survey of the Role of Noncovalent Sulfur Interactions in Drug Design J. Med. Chem. 2015, 58, 4383-4438 10.1021/jm501853m
18. Coe, J. W.; Dehnhardt, C. M.; Jones, P.; Kortum, S. W.; Sabnis, Y. A.; Wakenhut, F. M.; Whitlock, G. A. Indazoles. PCT Pat. Appl. WO2013014567, Jan. 31, 2013.
19. M of the respective enzyme.
20. Graczyk, P. P. Gini Coefficient: A New Way To Express Selectivity of Kinase Inhibitors against a Family of Kinases J. Med. Chem. 2007, 50, 5773-5779 10.1021/jm070562u
21. Davis, M. I.; Hunt, J. P.; Herrgard, S.; Ciceri, P.; Wodicka, L. M.; Pallares, G.; Hocker, M.; Treiber, D. K.; Zarrinkar, P. P. Comprehensive analysis of kinase inhibitor selectivity Nat. Biotechnol. 2011, 29, 1046-1051 10.1038/nbt.1990
22. A thorough description of the assay can be found in OECD (2004), Test No. 432: In Vitro 3T3 NRU Phototoxicity Test, OECD Guidelines for the Testing of Chemicals, Section 4; OECD Publishing: Paris.
23. Janssen, E. M. L.; Marron, E.; McNeill, K. Aquatic photochemical kinetics of benzotriazole and structurally related compounds Environ. Sci.: Processes Impacts 2015, 17, 939-946 10.1039/C5EM00045A